Clinical Trial Update: Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) [Phase 3]

View source ↗

Summary

Phase 3 study of patritumab with erlotinib in locally advanced or metastatic non-small cell lung cancer was terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• patritumab (patritumab)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Lung Cancer, Non-small Cell Lung Cancer | Phase 3 | Status: TERMINATED | Results posted: 2018-01-23